N
Neumirna Therapeutics
RNA drugs targeting microRNAs in neurological disease
About Neumirna Therapeutics
Neumirna Therapeutics is a Copenhagen-based biotech company developing antisense oligonucleotide (ASO) drugs that target microRNAs, small RNA molecules that regulate gene expression and help drive chronic neurological disease. By blocking disease-linked microRNAs, it aims to slow or reverse disease progression rather than only manage symptoms.
Its lead candidate, NMT.001, is an anti-miR ASO that inhibits miR-134 for drug-resistant epilepsy, a target first linked to seizures by researchers at RCSI and FutureNeuro in Dublin; clinical trials are planned for 2027. NMT.002 targets miR-27b in Parkinson's disease, and two further undisclosed programmes are in early screening. An in-house platform takes programmes from target identification through ASO design, screening and in vivo proof of concept.
The company works with academic partners including Aalborg University's Center for RNA Medicine and RCSI, and runs a team across Copenhagen, Basel and Boston. Its business model is to advance its own drug candidates through clinical development for patients with poorly served neurological disorders.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2025 | $22M | $88M | Angelini Ventures · Innovestor · Invivo Partners | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Neumirna Therapeutics is 540 monthly website visits, down 41.3% over the last three months. Neumirna Therapeutics's team grew 58.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Neumirna Therapeutics in the Copenhagen ecosystem
The Neumirna Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Angelini Ventures
Innovestor
Invivo Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Neumirna Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neumirna Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








